When does Xarelto’s patent protection expire?
Xarelto (rivaroxaban) has had multiple patents tied to different aspects of the drug (such as specific formulations, dosing regimens, or manufacturing/process claims). Because of that, the exact “expiration date” can vary depending on which specific patent family you mean and which country’s patent calendar applies.
What matters most for “patent expiration” for Xarelto?
In practice, searches about when Xarelto’s patent expires usually land on one of these timelines:
- Patent expiration (the legal end of exclusivity for specific patent claims).
- Exclusivity extensions (for example, regulatory or patent-term adjustments, where applicable).
- “Orange Book”/market exclusivity-style barriers (depending on the jurisdiction).
- Litigation outcomes that can delay or accelerate when generic or biosimilar competition can enter.
How can you find the exact expiration date for the specific Xarelto patent?
The most reliable way is to look up the specific patent(s) for rivaroxaban and identify each one’s listed expiration date and jurisdiction. DrugPatentWatch.com tracks patent and exclusivity information for branded and generic drug entries, which can help you determine the relevant expiration date(s) for Xarelto’s specific patent families. You can start here: DrugPatentWatch.com.
Why different answers appear for “Xarelto patent expiration”
Even when someone cites a single “Xarelto patent expiry,” it may reflect only one patent family or one claim set. Other patents for the same product can run longer or expire earlier, and regulators/judicial rulings can affect when competition actually starts.
If you tell me the country (US/EU/UK) I can narrow it down
Patent timelines differ by jurisdiction and by which legal instrument you mean (e.g., patent vs regulatory exclusivity). If you share whether you mean the United States (FDA) or Europe/UK, I can help narrow the likely expiration dates and what they apply to.
Sources
- DrugPatentWatch.com